Latigo Biotherapeutics’ imminent Nasdaq debut under ticker LTGO, with pricing terms set August 3 for 16 million shares at $16–$18, anchors trader sentiment around a $1.08–1.2 billion post-IPO market cap. Positive late-July NEJM publication of Phase 1 LTG-001 data in acute pain, combined with a Phase 3-ready non-opioid NaV1.8 pipeline and $322 million prior financing, supports the tight clustering of probabilities near $1–1.15 billion and $1.45 billion-plus bins. Biotech IPO momentum, recent board and CFO appointments, and the $247–285 million expected raise further shape implied odds, while lingering execution risk and broader market volatility keep the $1.3–1.45 billion and lower ranges competitive ahead of the August 7 listing.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateLatigo Biotherapeutics IPO Closing Market Cap
Latigo Biotherapeutics IPO Closing Market Cap
<$850M 0
$850M-$1B 0
$1B-$1.15B 0
$1.15B-$1.3B 0
BAGO
BAGO
Aug 7, 2026
<$850M
47%
$850M-$1B
48%
$1B-$1.15B
50%
$1.15B-$1.3B
47%
$1.3B-$1.45B
48%
$1.45B+
48%
No IPO before October 2026
47%
<$850M 0
$850M-$1B 0
$1B-$1.15B 0
$1.15B-$1.3B 0
BAGO
BAGO
Aug 7, 2026
<$850M
$80 Vol.
47%
$850M-$1B
$211 Vol.
48%
$1B-$1.15B
$111 Vol.
50%
$1.15B-$1.3B
$86 Vol.
47%
$1.3B-$1.45B
$45 Vol.
48%
$1.45B+
$75 Vol.
48%
No IPO before October 2026
$53 Vol.
47%
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics’ imminent Nasdaq debut under ticker LTGO, with pricing terms set August 3 for 16 million shares at $16–$18, anchors trader sentiment around a $1.08–1.2 billion post-IPO market cap. Positive late-July NEJM publication of Phase 1 LTG-001 data in acute pain, combined with a Phase 3-ready non-opioid NaV1.8 pipeline and $322 million prior financing, supports the tight clustering of probabilities near $1–1.15 billion and $1.45 billion-plus bins. Biotech IPO momentum, recent board and CFO appointments, and the $247–285 million expected raise further shape implied odds, while lingering execution risk and broader market volatility keep the $1.3–1.45 billion and lower ranges competitive ahead of the August 7 listing.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Binuksan ang Market: Aug 5, 2026, 5:52 AM ET
Volume
$661Petsa ng Pagtatapos
Aug 7, 2026Binuksan ang Market
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics’ imminent Nasdaq debut under ticker LTGO, with pricing terms set August 3 for 16 million shares at $16–$18, anchors trader sentiment around a $1.08–1.2 billion post-IPO market cap. Positive late-July NEJM publication of Phase 1 LTG-001 data in acute pain, combined with a Phase 3-ready non-opioid NaV1.8 pipeline and $322 million prior financing, supports the tight clustering of probabilities near $1–1.15 billion and $1.45 billion-plus bins. Biotech IPO momentum, recent board and CFO appointments, and the $247–285 million expected raise further shape implied odds, while lingering execution risk and broader market volatility keep the $1.3–1.45 billion and lower ranges competitive ahead of the August 7 listing.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$661Petsa ng Pagtatapos
Aug 7, 2026Binuksan ang Market
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...Latigo Biotherapeutics’ imminent Nasdaq debut under ticker LTGO, with pricing terms set August 3 for 16 million shares at $16–$18, anchors trader sentiment around a $1.08–1.2 billion post-IPO market cap. Positive late-July NEJM publication of Phase 1 LTG-001 data in acute pain, combined with a Phase 3-ready non-opioid NaV1.8 pipeline and $322 million prior financing, supports the tight clustering of probabilities near $1–1.15 billion and $1.45 billion-plus bins. Biotech IPO momentum, recent board and CFO appointments, and the $247–285 million expected raise further shape implied odds, while lingering execution risk and broader market volatility keep the $1.3–1.45 billion and lower ranges competitive ahead of the August 7 listing.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong